BACKGROUND INFORMATION ON THE PROCEDURE 
1 
Submission of the dossier 
The  applicant  Schering-Plough  Europe  submitted  on  26  July  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Aerinaze,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 27 April 2006.   
The legal basis for this application refers to:  
A - Centralised / Article 10(b) / Fixed combination application. 
The application submitted is a complete dossier composed of administrative information, complete 
quality data, non-clinical and clinical data based on applicants’ own tests and studies and/or 
bibliographic literature substituting/supporting certain test(s) or study(ies) 
Scientific Advice 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Pieter Neels 
Co-Rapporteur:  Heribert Pittner 
2 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 26 July 2006. 
The procedure started on 16 August 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  15 
November  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 30 October 2006.  
During  the  meeting  on  11-14  December  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 14 December 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
14 February 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 02 April 2007. 
The applicant submitted additional clarifications on 19 April 2007. 
The Rapporteurs circulated a revised Joint Assessment Report on 24 April 2007. 
During  the  CHMP  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 2 May 2007 
The Rapporteurs circulated a Joint Assessment Report on the responses to the List of 
Outstanding issues on 15 May 2007. 
During the meeting on 21 -24 May 2007 the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Aerinaze  on  24  May  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 22 May 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 30 July 2007. 
1/1 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
